1ZhongDF.Some aspects in establishing standard curves in bioanalyses with the weighted leastsquires method .药物分析杂志,1996,16:343-346. 被引量：2
2Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions [J]. Drugs, 1996,51(4):639-657. 被引量：1
3Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam [J]. Clin Pharmacokinet, 1998,34(6):421-428. 被引量：1
4Suwa T, Urano H, Shinohara Y, et al. Simultaneous high-performance liquid chromatogric determination of lornoxicam and its 5′-hydroxy metabolite in human plasma using electrochemical detection [J]. J Chromatogr, 1993,617(1):105-110. 被引量：1
5Radhofer-Welte S, Dittrich P. Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid [J]. J Chromatogr B, 1998,707(1-2):151-159. 被引量：1
6Shah VP, Midha KK, Hulse JD, et al. Bioanalytical methods validation -- a revisit with a decade of progress [J]. Pharm Res, 2000,17(12):1551-1557. 被引量：1
7Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam [J]. Eur J Clin Pharmacol, 1996,49(4):305-308. 被引量：1
